ULYM18086 / acalabrutinib -Barr IIT / Paul Barr
Research Question:
Is the combination of the drug acalabrutinib and antibody therapy, rituximab, safe
and effective in patients who have previously untreated chronic lymphocytic leukemia/small
lymphocytic lymphoma (CLL/SLL)?
Basic Study Information
Purpose:
The main purpose of this research study is to find out if the combination of acalabrutinib
and high frequency low dose subcutaneous rituximab is safe and effective in patients
who have previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL).
Location: University of Rochester Medical Center
Study Reference #: ULYM18086
Lead Researcher (Principal Investigator)
Lead Researcher:
Paul Barr
Study Contact Information
Study Coordinator: Lauren Mitchell
Email: lauren_mitchell@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search